Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Wound Care
- Biotechnology
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28726
'OSI Patents' shall mean all of Licensor's right, title and interest in and to the patents relating to TGF-Betas set out in Schedule 1 to the Agreement and corresponding foreign patents or applications therefore, together with any patents issuing on the said applications, or any addition, continuation, continuation-in-part, division, reissue, renewal or extension based thereon (including any supplementary protection certificate based on the said patents).
'OSI Know-How' shall mean all information and material, technical data and other know-how invented, developed or acquired by, or under the control of any party hereto and which directly relates to the Compound or the Product, or to the development, manufacture or use of the same, including but not limited to chemical data, toxicological and other pre-clinical data, product forms and formulations, control assays and specifications and methods of preparation and stability data, all such data belonging to one party constituting that party's confidential information.
'Products' shall mean pharmaceutical preparations containing the Compound designed for administration to human beings which fall within the scope of the claims of the OSI Patents.
'Licensed Indications' shall mean (1) oral mucositis arising from the use of chemotherapy or radiation therapy in the treatment or prevention of cancer, and (2) topical or local (as opposed to systemic) application of the Products including, but not limited to, the healing of soft tissue wounds however caused, and the treatment of ophthalmic conditions and psoriasis, but excluding topical application in the gastrointestinal tract in the treatment or prevention of cancer or the management of side effects or adverse reactions arising from the use in the treatment or prevention of cancer of chemotherapy or radiation therapy; and also (3) all other indications deemed to be included in the Licensed.
IPSCIO Record ID: 7497
Licensee may grant one sublicense under this license only to one other party in any country for each Systemic Use at any one time.
'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.
'TGF-beta 2' shall mean a protein comprising the amino acid sequence hereto, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.
'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.
'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.
Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.
'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.
IPSCIO Record ID: 230801
Licensor hereby grants to Licensee and Licensee hereby accepts for the term of this Agreement the non-transferable, exclusive, royalty-bearing license to use the Licensed Knowhow the Field of Use to make, have made, use, lease, sell and otherwise dispose of Licensed Products in the Licensed Territory.
Licensed Product means any product made, sold, or otherwise disposed of by or on behalf of Licensee which: (i) falls within the scope of, or utilizes any method or process that falls within the scope of, the Licensed Patents; or (ii) incorporates, or is itself, the invention which is the subject of the Licensed Patents; or (iii) embodies or uses, or the design, manufacture, production or sale of which embodies or uses, any of the Licensed Knowhow.
Licensed Patents means: (i) the patents and patent applications (and any patents issuing therefrom) listed and all foreign counterpart patents and patent applications; (ii) all continuation, divisional, extension, reissue patents and reexamination certificates granted thereon, including Supplementary Protection Certificates; and (iii) patents and patent applications (and any patents issuing therefrom) that may hereafter be filed by Licensor relating or pertaining to any Licensed Knowhow, together with all continuations, divisional, extension, reissue patents and reexamination certificates granted thereon, including Supplementary Protection Certificates.
Licensee Technology means all inventions, ideas, conceptions or reductions-to-practice, patentable or not, information, works and data that are generated, identified, discovered, created, made or controlled by Licensee, its employees or a third party on behalf of Licensee, relating to the Licensed Product or its production, including, without limitation, technical data, knowhow, chemical compounds, biological material, reports, manufacturing processes, formulations, modes of delivery and methods of use, pre-clinical and clinical data, documentation relating to regulatory submissions and marketing authorizations (including any Investigational New Drug Applications, New Drug Applications and equivalent documents), and post-registration clinical trial information and data relating to the Licensed Products.
Licensed Knowhow means all trade secrets, inventions, confidential or proprietary information and data: (i) that is disclosed to Licensee by or at the direction of Licensor or Licensor’s assignor; (ii) that is owned by or licensed to Licensor or Licensor’s assignor at the time of such disclosure; and (iii) that relates to the inventions that are the subject matter of the Licensed Patents. Licensed Knowhow includes, without limitation, technical data, knowhow, chemical compounds, biological material, reports, manufacturing processes, formulations, modes of delivery and methods of use, pre-clinical and clinical data, documentation relating to regulatory submissions and marketing authorizations (including any Investigational New Drug Applications, New Drug Applications and equivalent documents), and post-registration clinical trial information and data relating to the Licensed Products.
Licensee's goal is to perfonn clinical trials of abiraterone acetate that will support its indication as a second line therapy for patients with metastatic prostate cancer that has progressed following treatment with hormonal therapy that includes an LHRH agonist/antagonist and antiandrogen therapy.
